SCHEMBL17688369

SCHEMBL17688369

Cn1cc(-c2nc(N[C@@H]3CCC[C@H](NC(=O)OC(C)(C)C)C3)ncc2Cl)c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CDK7 P50613 13/20 0.49
▸ CCNH P51946 8/20 0.49
▸ CCNT1 O60563 8/20 0.49
▸ CDK9 P50750 8/20 0.49
▸ MNAT1 P51948 7/20 0.49
▸ CDK2 P24941 5/20 0.49
▸ CCNE1 P24864 2/20 0.49
▸ CCNK O75909 4/20 0.43
▸ CDK12 Q9NYV4 4/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ PIM2 Q9P1W9 1/20 0.43
▸ MAPK8 P45983 4/20 0.43
▸ MAPK9 P45984 4/20 0.43
▸ JUN P05412 3/20 0.43
▸ EGFR P00533 1/20 0.43
▸ CDK13 Q14004 1/20 0.43
▸ MAPK10 P53779 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20412348 0.91 CDK7 (0.46) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL17150726 0.90 CDK7 (0.45) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL19580260 0.88 CDK7 (0.53) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL19580261 0.88 CDK7 (0.53) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL16665090 0.87 CDK7 (0.47) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL20412340 0.87 CDK7 (0.47) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL21549476 0.87 CDK7 (0.48) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL16665125 0.84 CDK2 (0.60) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL16665578 0.84 HTR6 (0.46) CDK7CCNHCCNT1CDK9MNAT1
SCHEMBL18074045 0.84 HTR6 (0.46) CDK7CCNHCCNT1CDK9MNAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210061803-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2021-03-04 — — US disclosed
US-10865206-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2020-12-15 — — US disclosed
US-20190337940-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2019-11-07 — — US disclosed
US-10308648-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2019-06-04 — — US disclosed
US-20170327496-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2017-11-16 — — US disclosed
US-20170327496-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2017-11-16 — — US disclosed
WO-2016058544-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2016-04-21 — — WO disclosed
WO-2016058544-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2016-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337940-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNH 32/4885CCNT1 33/4885
US-10308648-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNH 32/4885CCNT1 33/4885
US-20170327496-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNH 32/4885CCNT1 33/4885
US-20210061803-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNH 32/4885CCNT1 33/4885
US-10865206-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNH 32/4885CCNT1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback